

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.

叮嚙健康科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 09886)

PROFIT ALERT – NARROWING OF LOSS

This announcement is made by Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2023 (the “**FY2023**”), the Group expects that as (i) the fair value losses on the Company’s preferred shares (which were issued to the Company’s pre-IPO investors) as financial liabilities at fair value through profit or loss and listing expenses did not recur for FY2023 after the completion of the Company’s listing of its shares on The Stock Exchange of Hong Kong Limited in September 2022, and (ii) share-based payments expenses decreased during FY2023, the loss for FY2023 may be narrowed by more than 85% as compared to the loss of RMB2,842.3 million for the year ended December 31, 2022.

The Company is still in the process of finalizing the annual results for the Group for FY2023. The information contained in this announcement is only a preliminary assessment by the Board based on the figures and information currently available, and is not audited or reviewed by the auditor or the audit committee of the Company and may be subject to adjustments. Shareholders and potential investors of the Company should refer to and carefully read the annual results announcement of the Company for FY2023, which is expected to be published in March 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
YANG WENLONG
Chairman

Hong Kong, February 28, 2024

As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei, Mr. YU Qinglong and Mr. YANG Yibin, the non-executive Director is Ms. CAI Li, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.